加载中
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
前收盘价
US$8.21
−US$0.19 · -2.26%
盘后
US$8.21
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
日内区间
当前US$8.21
52周区间
当前US$8.21
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
51
合理估值
情绪
62
看涨
风险
42
风险偏高
动量
37
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
日内区间
当前US$8.21
52周区间
当前US$8.21
| 项目（USD） | 2025财年 |
|---|---|
| 营收 | 1861.8万 USD |
| 毛利 | 1861.8万 USD |
| 研究与开发 | 5375.6万 USD |
| 销售、一般及管理费用 | 4167.6万 USD |
| 营业费用 | 9543.2万 USD |
| 折旧和摊销 | 32.3万 USD |
| 营业利润 | −7681.4万 USD |
| 净利润 | −7668.4万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI690.53万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM321.26万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF251.25万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO109.95万0.01%180亿 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO82.42万0.01%139.17亿 USD0.24%US$353.71-0.86%
Schwab U.S. Small-Cap ETFSCHA72.19万0.00%218.24亿 USD0.03%US$32.66-0.40%
iShares Micro-Cap ETFIWC39.37万0.03%13.17亿 USD0.60%US$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM17万0.14%1.16亿 USD0.73%US$15.8484-0.58%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
